December 2019 Hematology and Oncology journal

The Role of Comprehensive Molecular Profiling in Colorectal Cancer

Howard S. Hochster, MD

  H&O  What are the relevant mutations or other alterations that molecular profiling can pick up in colorectal cancer, and how common are they? HH  The […]

In This Issue

Treatment-Free Remission in Chronic Myeloid Leukemia

Matteo Molica, MD, Kiran Naqvi, MD, Jorge E. Cortes, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Massimo Breccia, MD, Hagop Kantarjian, MD, and Elias J. Jabbour, MD

Bladder-Sparing Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer

Kyle J. Ericson, MD, Prithvi B. Murthy, MD, Darren J. Bryk, MD, Rathika R. Ramkumar, MD, James R. Broughman, MD, Abhinav Khanna, MD, MPH, Omar Y. Mian, MD, and Steven C. Campbell, MD, PhD

From Recent Issues

Treatment of Early-Stage Hormone Receptor–Positive Breast Cancer

H&O  What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR  […]

Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors

  H&O  What is the KRAS G12C mutation? DH RAS mutations are one of the most common mutations in cancer (after the P53 mutation). Estimates suggest […]

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time 

  Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]


Highlights From the XVIII International Workshop on Chronic Lymphocytic Leukemia

A Review of Selected Presentations From the XVIII iwCLL • September 20-23, 2019 • Edinburgh, Scotland Ibrutinib Versus Placebo in Patients With Asymptomatic, Treatment-Naive Early-Stage Chronic […]

A New Strategy for Uncontrollable Bleeding After Treatment With Rivaroxaban or Apixaban

Abstract: Anticoagulants are used in several settings to reduce the risk of thromboembolic events, but they can be associated with severe complications, such as potentially fatal bleeding. […]

Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Brentuximab Vedotin With Chemotherapy for Stage 3/4 […]